Exicure sells core SNA technology to Flashpoint for $1.5M; appoints new director

EXICURE, INC.

Sold spherical nucleic acid technology, R&D programs, and clinical assets to Flashpoint Therapeutics for $1.5 million gross proceeds.
Will receive royalties on future licensing or sublicensing of the assets by Flashpoint.
Board increased to seven; Eui Yull Hwang appointed as independent Class II director.
No material relationship exists between Exicure and Flashpoint aside from the transaction.

item 1.01 item 2.01 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Eui Yull Hwang

Independent Director

XCUR · EXICURE, INC.

Effective: 2024-09-26
Filed: September 30, 2024, 7:59 PM ET

On September 26, 2024, the Board increased the size of the Board from six directors to seven directors and appointed Eui Yull Hwang as an independent director to fill the vacancy.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Eui Yull Hwang was appointed as Independent Director at EXICURE, INC..

Action: appointed
Role: Independent Director

Exact text from the filing

On September 26, 2024, the Board increased the size of the Board from six directors to seven directors and appointed Eui Yull Hwang as an independent director to fill the vacancy.

View on SEC.gov

EXICURE, INC. filing history →

Source: SEC EDGAR

accession 0001698530-24-000110

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.